Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -11.6 Million USD | 58.13% |
| 2021 | -27.72 Million USD | -139.68% |
| 2020 | -11.56 Million USD | -330.07% |
| 2019 | -2.68 Million USD | -292.14% |
| 2018 | -685.96 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -2.44 Million USD | -41.54% |
| 2023 Q2 | -2.61 Million USD | -6.81% |
| 2022 FY | -11.6 Million USD | 58.13% |
| 2022 Q4 | -1.73 Million USD | 8.84% |
| 2022 Q3 | -1.89 Million USD | 42.81% |
| 2022 Q2 | -3.31 Million USD | 28.78% |
| 2022 Q1 | -4.66 Million USD | 28.5% |
| 2021 Q3 | -1.4 Million USD | 91.04% |
| 2021 FY | -27.72 Million USD | -139.68% |
| 2021 Q1 | -3.4 Million USD | -224.03% |
| 2021 Q2 | -15.62 Million USD | -358.96% |
| 2021 Q4 | -6.51 Million USD | -365.52% |
| 2020 Q4 | -1.05 Million USD | 9.4% |
| 2020 Q1 | -626.13 Thousand USD | 35.04% |
| 2020 Q2 | -8.02 Million USD | -1181.71% |
| 2020 FY | -11.56 Million USD | -330.07% |
| 2020 Q3 | -1.15 Million USD | 85.55% |
| 2019 Q4 | -963.88 Thousand USD | -20.91% |
| 2019 FY | -2.68 Million USD | -292.14% |
| 2019 Q3 | -797.22 Thousand USD | -82.35% |
| 2019 Q2 | -437.18 Thousand USD | 11.08% |
| 2019 Q1 | -491.65 Thousand USD | 0.0% |
| 2018 Q1 | -122.48 Thousand USD | 0.0% |
| 2018 Q2 | -152.22 Thousand USD | -24.28% |
| 2018 FY | -685.96 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -1424.76% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -34.498% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 62.243% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 90.646% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 27.791% |
| Better Therapeutics, Inc. | -39.76 Million USD | 70.8% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 38.462% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 36.827% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 67.58% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 67.809% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 89.863% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -416.392% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 84.469% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 80.35% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -93.876% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 45.478% |
| Molecular Templates, Inc. | -8.12 Million USD | -42.908% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 23.505% |
| NexImmune, Inc. | -32.34 Million USD | 64.106% |
| Orgenesis Inc. | -55.36 Million USD | 79.029% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 54.044% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -14781.15% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 36.523% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 97.973% |
| Statera Biopharma, Inc. | -174.4 Million USD | 93.343% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -223.574% |
| Trevena, Inc. | -40.28 Million USD | 71.184% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -20291.729% |
| Vaccinex, Inc. | -20.25 Million USD | 42.67% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -882.126% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 77.261% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -49.281% |